AU2011362905B2 - Pharmaceutical composition for treating hepatic disease - Google Patents

Pharmaceutical composition for treating hepatic disease Download PDF

Info

Publication number
AU2011362905B2
AU2011362905B2 AU2011362905A AU2011362905A AU2011362905B2 AU 2011362905 B2 AU2011362905 B2 AU 2011362905B2 AU 2011362905 A AU2011362905 A AU 2011362905A AU 2011362905 A AU2011362905 A AU 2011362905A AU 2011362905 B2 AU2011362905 B2 AU 2011362905B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
liver
proanthocyanidin
bel
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011362905A
Other languages
English (en)
Other versions
AU2011362905A1 (en
Inventor
Shau-Feng Chang
Kai-wen HUANG
Chien-Tung Lin
Shyh-Horng Lin
Chun-Hsien Ma
Kuo-Yi Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belx Bio Pharmaceutical Taiwan Corp
Original Assignee
Belx Bio Pharmaceutical Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belx Bio Pharmaceutical Taiwan Corp filed Critical Belx Bio Pharmaceutical Taiwan Corp
Publication of AU2011362905A1 publication Critical patent/AU2011362905A1/en
Application granted granted Critical
Publication of AU2011362905B2 publication Critical patent/AU2011362905B2/en
Assigned to BELX Bio-Pharmaceutical (Taiwan) Corporation reassignment BELX Bio-Pharmaceutical (Taiwan) Corporation Request for Assignment Assignors: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2011362905A 2011-03-22 2011-03-22 Pharmaceutical composition for treating hepatic disease Active AU2011362905B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/072045 WO2012126178A2 (zh) 2011-03-22 2011-03-22 减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物

Publications (2)

Publication Number Publication Date
AU2011362905A1 AU2011362905A1 (en) 2013-10-31
AU2011362905B2 true AU2011362905B2 (en) 2015-11-12

Family

ID=46879777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011362905A Active AU2011362905B2 (en) 2011-03-22 2011-03-22 Pharmaceutical composition for treating hepatic disease

Country Status (13)

Country Link
EP (1) EP2689777B1 (enExample)
JP (1) JP6166251B2 (enExample)
KR (2) KR101981378B1 (enExample)
CN (1) CN103442709B (enExample)
AU (1) AU2011362905B2 (enExample)
CA (1) CA2830616C (enExample)
DK (1) DK2689777T3 (enExample)
ES (1) ES2668785T3 (enExample)
NO (1) NO2689777T3 (enExample)
PL (1) PL2689777T3 (enExample)
RU (1) RU2561688C2 (enExample)
SG (1) SG193486A1 (enExample)
WO (1) WO2012126178A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179774A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
CN104774909A (zh) * 2014-10-17 2015-07-15 江苏大学 一种原花青素诱导肝癌细胞自噬性死亡的分析方法及应用
GB201909709D0 (en) * 2019-07-05 2019-08-21 Univ Liverpool Biomarkers for irritable bowel syndrome
WO2022080846A1 (ko) * 2020-10-13 2022-04-21 서울대학교병원 플라본을 포함하는 섬유증의 예방 또는 치료용 조성물
WO2022205137A1 (zh) * 2021-03-31 2022-10-06 贝尔克斯生技股份有限公司 高聚原花青素组合物及其应用
CN115010720B (zh) * 2022-06-02 2023-08-11 中国科学院昆明植物研究所 中甸艾中倍半萜二聚体及其药物组合物与其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1443533A (zh) * 2002-03-07 2003-09-24 程彦杰 原花青素类化合物在用于制备解酒保肝产品方面的用途
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
CN1933818A (zh) * 2004-01-30 2007-03-21 马尔斯公司 用于治疗癌症的方法和组合物
JP2009242374A (ja) * 2008-03-14 2009-10-22 Miyazakiken Sangyo Shien Zaidan 肝線維化抑制剤
CN101822372A (zh) * 2009-03-05 2010-09-08 财团法人工业技术研究院 用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
TW200505468A (en) * 2003-08-11 2005-02-16 Suntory Ltd Agent for improving hepato-bililary dysfunction
JP2008156265A (ja) * 2006-12-22 2008-07-10 Yamagata Prefecture Ａ型プロアントシアニジンオリゴマー画分及びその製造方法
JP2008195672A (ja) * 2007-02-14 2008-08-28 Okayama Univ 経口摂取用組成物及び経口摂取用組成物の製造方法
TWI370736B (en) * 2008-12-31 2012-08-21 Ind Tech Res Inst Pharmaceutical composition for treating hepatitis b and heath food for inhibiting hepatitis b virus
CN101507730B (zh) * 2009-03-26 2011-01-26 复旦大学 表没食子儿茶素没食子酸酯与柔红霉素的组合物及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1443533A (zh) * 2002-03-07 2003-09-24 程彦杰 原花青素类化合物在用于制备解酒保肝产品方面的用途
CN1933818A (zh) * 2004-01-30 2007-03-21 马尔斯公司 用于治疗癌症的方法和组合物
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
JP2009242374A (ja) * 2008-03-14 2009-10-22 Miyazakiken Sangyo Shien Zaidan 肝線維化抑制剤
CN101822372A (zh) * 2009-03-05 2010-09-08 财团法人工业技术研究院 用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE, S. J. ET AL., Ann. N. Y. Acad. Sci., 2007, Vol. 1095, pages 536-544 *
WEIGUANG, Y. ET AL., Food Research International, 2006, Vol. 39, pages 628-638 *

Also Published As

Publication number Publication date
PL2689777T3 (pl) 2018-08-31
CN103442709A (zh) 2013-12-11
JP2014508785A (ja) 2014-04-10
WO2012126178A3 (zh) 2012-11-22
RU2013146602A (ru) 2015-04-27
KR101981378B1 (ko) 2019-05-22
ES2668785T3 (es) 2018-05-22
KR20140020966A (ko) 2014-02-19
KR20160143868A (ko) 2016-12-14
CA2830616C (en) 2017-02-21
CA2830616A1 (en) 2012-09-27
DK2689777T3 (en) 2018-05-22
CN103442709B (zh) 2018-10-19
EP2689777A4 (en) 2014-09-17
EP2689777A2 (en) 2014-01-29
NO2689777T3 (enExample) 2018-08-25
AU2011362905A1 (en) 2013-10-31
WO2012126178A2 (zh) 2012-09-27
RU2561688C2 (ru) 2015-08-27
JP6166251B2 (ja) 2017-07-19
SG193486A1 (en) 2013-10-30
EP2689777B1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
AU2011362905B2 (en) Pharmaceutical composition for treating hepatic disease
KR100685083B1 (ko) 사이클로옥시게나제-2 억제제로서 효능있는 프리-비-링구조를 갖는 플라보노이드의 선별
Wang et al. Protective effects of Punica granatum (pomegranate) peel extract on concanavalin A-induced autoimmune hepatitis in mice
RU2644635C2 (ru) Системы, способы и составы для лечения рака
KR100545723B1 (ko) 솔라눔속 식물의 수용성 추출물, 그 제조방법, 및 그수용성 추출물을 함유하는 약제학적 조성물
RU2697670C2 (ru) Фармацевтическая композиция, содержащая силибин и экстракт корня пуэрарии
Zhang et al. Protective action of pomegranate peel polyphenols in type 2 diabetic rats via the translocation of Nrf2 and FoxO1 regulated by the PI3K/Akt pathway
CN105963637B (zh) 隐丹参酮联合姜黄素在制备肿瘤治疗药物中的应用
JP2010155840A (ja) Ｂ型肝炎を治療するための医薬組成物およびｂ型肝炎ウイルス抑制効果を有する健康食品
WO2014131213A1 (zh) 表没食子儿茶素没食子酸酯的制备方法及其用途
Shi et al. A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells
Pradhan et al. Cardioprotective effects of Rhododendron arboreum leaf extract against Doxorubicin-induced cardiotoxicity in Wistar rats by modulating electrocardiographic and cardiac biomarkers
US20120201903A1 (en) Cytoprotective or therapeutic plant composition
WO2019055513A1 (en) INHIBITED PD-L1 EXPRESSION AND ENHANCED PD-1 EXPRESSION
TWI458487B (zh) 藥學組合物之用途
Kuo et al. Protection of Chinese olive fruit extract and its fractions against advanced glycation endproduct-induced oxidative stress and pro-inflammatory factors in cultured vascular endothelial and human monocytic cells
WO2006122274A2 (en) Pharmaceutical formulations of rhodiola crenulata and methods of use thereof
US20130123204A1 (en) Method for treating hepatitis b
CN111529569B (zh) 一种治疗非酒精性脂肪肝的组合物及用途
CN113185562B (zh) 暗绿蒿素a-p及其药物组合物与其制备方法和应用
CN104220063A (zh) 利用细福寿草提取物或其有效物质的抗癌剂组合物
HK1188720B (zh) 减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物
Ghaffar et al. The hematological and histological studies for the hepatoprotective-like effect of the hydromethanolic extract and the fractions of Viola serpens Wall.
WO2005063235A1 (en) Anticancer therapy-aiding composition comprising polyphenol, and ascorbic acid or the derivatives
HK1188720A (en) A pharmaceutical composition for alleviating aggravation of hepatoma, improving hepatic function, improving hepatic fibrosis, improving hepatic cirrhosis, improving hepatitis and promoting injured liver regeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BELX BIO-PHARMACEUTICAL (TAIWAN) CORPORATION

Free format text: FORMER OWNER(S): INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE